The CAMHS neurodevelopmental crisis is a generational failure. Children are being identified as struggling by their teachers and parents — sometimes years before they receive any clinical assessment — while they fall further behind academically, socially, and emotionally. The gap between identification and assessment is not measured in weeks. It is measured in years. In missed EHCPs. In exclusions. In mental health crises that could have been prevented with earlier support.

Allo Paediatrics is being developed to create a structured, clinically-supervised pathway between identification and assessment — reducing the burden on an overstretched CAMHS system by ensuring that, when a specialist clinician finally sees a child, they are not starting from zero. They are starting from a comprehensive, multi-informant, clinically organised profile of that child's neurodevelopmental presentation, synthesised from the voices of the people who know them best: the child themselves, their parents or carers, and their teachers.

Why children are missed — and how Allo Paediatrics addresses it
Neurodevelopmental conditions present differently in children than in adults, and differently again across age bands, genders, and cultural contexts. The diagnostic tools in routine CAMHS use were not designed for the full spectrum of presentations. Girls with ADHD are systematically under-identified because their presentations are predominantly inattentive and internalised rather than hyperactive and externalised. Children from under-represented ethnic communities are less likely to receive timely referral. Children who have learned to mask their difficulties — often the most able, and therefore the most underserved — are routinely missed entirely.

Allo Paediatrics is being designed to surface these hidden presentations — not by replacing clinical judgement, but by gathering richer, more representative information than any single assessment appointment can provide. The platform combines multiple sources of structured observational data — from the child, from home, and from school — and synthesises them through a clinically validated framework that the CAMHS clinician can interrogate, challenge, and act upon.

The child's voice is at the centre of this. Children are not just the subject of neurodevelopmental assessment — they are participants in it. Allo Paediatrics is being designed so that children aged 5 to 17 can contribute meaningfully to their own profile, in age-appropriate ways, with full safeguarding oversight embedded at every point.

Safeguarding and clinical safety are non-negotiable
Allo Paediatrics is being built with the understanding that a platform touching children's mental health and neurodevelopmental data carries the highest possible clinical responsibility. The safeguarding architecture, the clinical safety framework, and the data governance model are all being designed to the standard expected of a regulated medical device — because that is exactly what this is. No output is generated without clinician review. No safeguarding signal is ignored. No data is processed without appropriate consent and governance. This is not a self-referral app. It is a clinical support tool, designed for use within — and accountable to — clinical systems.